Loneliness and the aging population

How businesses and governments can address a looming crisis

Download PDF Report

Download PDF report

You might also like:


Blockchain revolution in education and lifelong learning

Read Next


Executive overview

Authors: Nicola Palmarini

Connect with author:


, Global manager for Aging and Accessibility solutions,
Heather Fraser

Connect with author:


, Global Lead for Healthcare and Life Sciences, IBM Institute for Business Value,
Sheila Zinck

Connect with author:


, Advocacy and Eminence programs lead,
Rebecca Wu

Connect with author:


, Business Analytics and Strategy consultant

Improving how older adults engage with the world For the aging population, loneliness is more than a state of mind – it is an emerging risk factor that has implications for personal, economic and societal well-being. A range of stakeholders, including business leaders, medical professionals, governments, advocacy groups and social service organizations, has a significant interest in preventing, identifying and addressing the root causes of loneliness. Without countermeasures, older adults face continued detachment from the mainstream, even as their numbers grow. Our newest research explores how organizations in many industries can act to help older adults strengthen their social fabric and reconnect to others.


How can IBM help you?

Helping family and caregivers to proactively monitor the health and well-being of our seniors

Atmospheric, motion & falling, audio, and olfactory sensors can improve health and wellness


Related reports
Developed in collaboration with the Blockchain Research Institute, this report explores how blockchain is transforming education with an emphasis on lifelong learning and reskilling the workforce.
When it comes to how digital therapy will impact healthcare, personalization and individualization and greater patient engagement stand out.
Learn how public and private sector leaders can work together to foster national and regional economic competitiveness in an era of uncertainty.
To help accelerate drug discovery, leading organizations and researchers are turning to artificial intelligence (AI) because it can reveal hidden patterns in data.